The growing interest in minimal residual disease (MRD)assessment in multiple myeloma (MM) is related to thehigh quality of responses achieved with novel agents andto the development of reliable techniques to evaluateMRD both within the bone marrow using next-generationsequencing (NGS) or next-generationflow cytometry(NGF), and outside the bone marrow using imagingtechniques, such as positron emission tomography-computed tomography (PET-CT)1. A consensus paperby the International Myeloma Working Group (IMWG),published in 2016, represents the reference document onMRD in MM2.
MRD in multiple myeloma: more questions than answers?
Zamagni Elena
2017
Abstract
The growing interest in minimal residual disease (MRD)assessment in multiple myeloma (MM) is related to thehigh quality of responses achieved with novel agents andto the development of reliable techniques to evaluateMRD both within the bone marrow using next-generationsequencing (NGS) or next-generationflow cytometry(NGF), and outside the bone marrow using imagingtechniques, such as positron emission tomography-computed tomography (PET-CT)1. A consensus paperby the International Myeloma Working Group (IMWG),published in 2016, represents the reference document onMRD in MM2.File in questo prodotto:
| File | Dimensione | Formato | |
|---|---|---|---|
|
mrd.pdf
accesso aperto
Tipo:
Versione (PDF) editoriale
Licenza:
Licenza per Accesso Aperto. Creative Commons Attribuzione (CCBY)
Dimensione
242.3 kB
Formato
Adobe PDF
|
242.3 kB | Adobe PDF | Visualizza/Apri |
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
